# <sup>1</sup>**ENDORSE: a prognostic model for endocrine therapy response in advanced**

### <sup>2</sup>**estrogen-receptor positive breast cancers**

- 3 Aritro Nath<sup>1</sup>, Adam L. Cohen<sup>2</sup> and Andrea H. Bild<sup>1\*</sup>
- 4
- $15<sup>-1</sup>$  Department of Medical Oncology and Therapeutics, City of Hope Comprehensive
- <sup>6</sup>Cancer Institute, Monrovia, California
- 7 <sup>2</sup> Neuro Oncology Program, Inova Schar Cancer Institute, Fairfax, Virginia
- 8
- <sup>9</sup>\*Correspondence: Andrea H. Bild, Ph.D.
- 10 Professor, Department of Medical Oncology and Therapeutics
- 11 City of Hope Comprehensive Cancer Institute
- <sup>12</sup>1218 S Fifth Ave, Monrovia, CA 91016
- <sup>13</sup>(626) 218-6052
- 14 abild@coh.org
- 15
- 16 Conflict of interest statement: The authors declare no potential conflicts of interest.

# <sup>17</sup>**ABSTRACT**

<sup>18</sup>Endocrine therapy remains the primary treatment for advanced and metastatic estrogen 19 receptor-positive (ER+) breast cancers. Patients who progress on endocrine therapy <sup>20</sup>may benefit from add-on treatment targeting the PI3K/MTOR signaling pathways or by 21 switching to chemotherapy. However, these options are only available after progression 22 on first-line treatment with endocrine therapy. In the absence of reliable prognostic tests 23 for advanced ER+ breast cancers, it is currently not possible to stratify patients into 24 pertinent treatment arms at the baseline. To address this, we have developed a low-25 dimensional endocrine response signature (ENDORSE) model for advanced ER+ 26 breast cancers. The ENDORSE model was developed using the baseline tumor 27 transcriptomes and long-term survival outcomes of >800 invasive ER+ breast cancers 28 and predicts the risk of death on endocrine therapy. ENDORSE was validated in 29 multiple clinical trial datasets for endocrine therapy response in metastatic ER+ breast 30 cancers and demonstrated superior predictive performance over clinical factors and 31 published gene signatures. Our results show that ENDORSE is a reproducible and 32 accurate prognostic model for endocrine therapy response in advanced and metastatic <sup>33</sup>ER+ breast cancers.

### <sup>35</sup>**INTRODUCTION**

36 Breast cancer is the most common form of cancer globally, with more than two million  $37$  cases diagnosed in 2020<sup>1</sup>. Pathogenesis and classification of breast cancer is based on  $38$  the presence or absence of estrogen receptor alpha (ER), progesterone receptor (PR) 39 and human growth factor-neu receptor (HER2). These subtypes guide the selection of <sup>40</sup>systemic therapy for breast cancer patients. More than 70% of breast cancers express 41 ER and are negative for HER2 (ER+/HER2-)<sup>2,3</sup>. The primary systemic therapy for 42 ER+/HER2- breast cancer is endocrine therapy, which counters the growth of tumors by  $43$  targeting their dependency on estrogen signaling<sup>4</sup>. This includes selective estrogen 44 receptor modulators (SERMs) such as tamoxifen and selective estrogen receptor 45 degraders (SERDs) such as fulvestrant that directly prevent ER activation, or aromatase 46 inhibitors like exemestane and anastrozole that reduce circulating levels of estrogen in  $47$  the body  $5,6$ . Endocrine therapy substantially reduces the risk of recurrence within 5-48 years, although chemotherapy may be recommended for some patients with high risk of 49 recurrence. While clinicopathological features are not reliable predictors of recurrence 50 risk, gene expression-based genomic tests that predict the risk of recurrence can aid in 51 deciding whether the benefit of adding chemotherapy outweighs its side effects in  $52$  certain patients<sup>7,8</sup>. These biomarkers are have been validated and recommended for 53 clinical use only in early stage, node-negative cancers based on guidelines from the 54 American Society of Clinical Onoclogy and European Group on Tumor Markers<sup>9,10</sup>. 55

<sup>56</sup>Locally advanced and metastatic ER+ breast cancers often develop resistance to 57 endocrine therapy with significantly higher rates of recurrence and death compared to

 $\mathfrak{S}$ 

58 early-stage disease. Despite these challenges, single-agent endocrine therapy or in 59 combination with CDK4/6 inhibitors remains the primary systemic therapy  $60$  recommended for locally advanced and metastatic breast cancers<sup>11</sup>. Patients may 61 benefit from the addition of targeted inhibitor against the mTOR or PI3K pathways<sup>12,13</sup> or 62 switching to chemotherapy<sup>11</sup>. However, these treatment options are recommended for 63 consideration only upon progression on endocrine therapy, according to the American 64 Society for Clinical Oncology<sup>14</sup>, National Comprehensive Cancer Network  $15,16$  and  $65$  European Society for Medical Oncology  $^{17}$  clinical practice guidelines. Therefore, the 66 ability to predict the potential benefit from first-line endocrine therapy may be crucial for  $67$  locally advanced and metastatic ER+ breast cancers that may benefit from continued <sup>68</sup>endocrine therapy, a combination treatment or chemotherapy as the primary treatment 69 strategy.

70

71 Unlike early stage, node-negative disease, genomic tests for endocrine therapy response are not available for advanced and metastatic ER+ breast cancers. To address this limitation, a few attempts have been made so far to develop a genomic signature of endocrine response in ER+ metastatic breast cancers (ER+ MBC)<sup>18,19</sup>. The 75 TransCONFIRM trial evaluated the transcriptomes of 112 ER+/HER2- MBCs and 76 identified a set of 37 genes that were associated with progression-free survival (PFS) of patients receiving fulvestrant<sup>19</sup>. Another study analyzed the transcriptomes of 140 ER+/HER2- MBC on endocrine therapy to develop SET ER/PR, an 18-gene predictive score for endocrine therapy sensitivity  $^{18}$ . While both the TransCONFIRM and SET ER/PR biomarkers predicted endocrine response in their respective training datasets,

81 Somer study performed systematic validation of their predictive signatures to 82 demonstrate the reproducibility and accuracy in independent clinical datasets. This 83 issue highlights a critical flaw in biomarker development pipelines and is one important 84 reason why genomic biomarkers are infrequently translated into clinical practice<sup>20</sup>. 85 Another pervasive issue hindering clinical translation arises from the reliance on a large 86 number of predictive features in complex models that are difficult to interpret and often 87 perform poorly in independent validation due to overfitting  $2^{1,22}$ . 88 <sup>89</sup>Here we developed ENDORSE: a low-dimensional expression-based prognostic model 90 for endocrine therapy and systemically tested its performance and predictive ability in <sup>91</sup>multiple-independent clinical trials against other diagnostic models and genomic 92 signatures. ENDORSE was developed and trained using the tumor transcriptomes and 93 overall survival (OS) of more than 800 ER+ breast cancers on endocrine therapy<sup>23,24</sup>. <sup>94</sup>We validated the ENDORSE model in multiple independent clinical trial datasets, 95 including the TransCONFIRM and SET ER/PR trials for endocrine therapy in metastatic <sup>96</sup>ER+ breast cancer. Our results show that ENDORSE reproducibly predicts endocrine 97 response in independent validation clinical studies, and consistently outperforms all 98 other models of endocrine therapy response in metastatic ER+ breast cancers, clinical

99 factors, and proliferation signatures.

#### <sup>100</sup>**RESULTS**

<sup>101</sup>**Developing a low-dimensional prognostic model for endocrine therapy** 

<sup>102</sup>We developed a two-component prognostic model for endocrine therapy response

<sup>103</sup>using the tumor transcriptomes and long-term survival outcomes of 833 ER+/HER2-

104 tumors that received endocrine therapy<sup>23,24</sup> (Table 1, Figure 1a). About 2 in 5 tumors in 105 this training cohort were node-positive, while more than a third of the tumors were 106 poorly differentiated, grade 3 tumors (Table 1). The two components included an  $107$  empirical gene signature modeled on OS (median = 10 years) and a curated gene  $108$  signature defining response to estrogen<sup>25</sup>. Figure 1a outlines the inclusion criteria for 109 the training dataset, method for developing the empirical gene signature and the final <sup>110</sup>Cox proportional hazards model based on the gene set enrichments scores (GES) of <sup>111</sup>the two signatures. The empirical signature was developed by first performing a feature 112 selection on the training dataset using a repeated cross-validation analysis of a lasso-113 regularized proportional hazards model. Each iteration yielded a core set of predictive 114 features that were expanded to a correlation network. The final gene signature was 115 derived from the consensus correlation network, defined as genes appearing in at least 116 50% of the cross-validation iterations (Supplementary Figure 1, Supplementary Table 117 1). In a bivariate Cox proportional hazards model of the training data, the empirical 118 signature was associated with a reduction in survival probability, while the estrogen 119 response signature was associated with improved survival (Figure 1b). The coefficients 120 for the endocrine response, or ENDORSE, model was calculated using the training 121 cohort, resulting in ENDORSE = 1.54 x (empirical signature GES) – (2.72 x estrogen <sup>122</sup>response GES). The ENDORSE model could also be used to stratify the tumors based 123 on predicted risk, for example by setting a threshold of  $\geq$ 2-fold relative risk of death as <sup>124</sup>"high-risk" and ≤1 risk as "low-risk", resulting in significant differences in the Kaplan-125 Meier survival curves across the strata  $(P = 3 \times 10^{-14})$  (Figure 1c).

127



128

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.<br>All rights reserved. No reuse allowed without permission. medRxiv preprint doi: [https://doi.org/10.1101/2021.02.03.21251035;](https://doi.org/10.1101/2021.02.03.21251035) this version posted November 9, 2021. The copyright holder for this preprint

#### 130



<sup>132</sup>**Figure 1: ENDORSE model development in METABRIC.** A. Inclusion criteria and 133 overall schematic of ENDORSE model development. Samples for training were selected 134 based on ER+ status and excluded from the analysis if they were either HER2+, 135 received chemotherapy in addition to hormone therapy, died due to other causes <sup>136</sup>besides breast cancer, or were missing transcriptomic or survival data. The empirical 137 signature was developed using a repeated cross-validation analysis framework. Each 138 iteration of the lasso-regularized proportional hazards model generated a feature set 139 (seed genes) predictive of OS. The seed genes were expanded to a network of 140 intercorrelated genes, and the final empirical signature was defined by identifying a 141 consensus set across all iterations. The two-feature ENDORSE model was then 142 constructed using the gene set enrichment scores of the empirical signature and 143 estrogen response signature. B. Predicted 10-year survival probabilities of the 833

- 144 ER+/HER2- METABRIC breast cancers based on a Cox proportional hazards model of
- 145 gene signature enrichment scores of the empirical and estrogen response signatures as
- 146 predictor variables. C. Kaplan-Meier curves and risk tables of METABRIC ER+/HER2-
- 147 tumors stratified by ENDORSE. The tumors were stratified according to an ENDORSE
- 148 risk score (hazard ratio) threshold of ≥2 to define high-risk, ≤1 as low risk and all other
- 149 intermediate values as medium risk.

#### <sup>151</sup>**Internal performance evaluation, comparison with clinical covariates and**

#### <sup>152</sup>**published breast cancer signatures**

153 We performed bootstrap resampling analyses to validate the Cox model in the training

- 154 dataset (Figure 2a) and performed likelihood ratio tests (Figure 2b) to compare with
- 155 other univariate prognostic models including clinical factors, proliferation index and
- 156 published prognostic signatures for ER+ breast cancers. First, we compared the
- 157 ENDORSE model to the univariate models based on the individual components of
- 158 ENDORSE, i.e., the empirical signature and estrogen response signature. The
- 159 ENDORSE model (Somer's D or  $D_{xy} = 0.301$ ) was a better fit than the empirical

160 signature ( $D_{xy} = 0.296$ , P = 1.09 x 10<sup>-3</sup>) and the estrogen response signature ( $D_{xy} =$ 

161 0.141, P = 3.93 x 10<sup>-14</sup>) univariate models.

162

<sup>163</sup>We then compared ENDORSE with clinical factors, such as tumor grade and mutation 164 burden. The ENDORSE model performed better than both tumor grade ( $D_{xy} = 0.141$ , P  $165 = 2.08 \times 10^{-3}$ ) and mutation count (D<sub>xy</sub> = 0.059, P = 9.76 x 10<sup>-6</sup>). We also compared the <sup>166</sup>model with a 'meta-PCNA' proliferation index that was reported to capture the 167 prognostic ability of most published signatures of breast cancer<sup>26,27</sup>. Again, the 168 ENDORSE model performed significantly better than the proliferation index ( $D_{xy}$  = 169 0.235, P = 4.42 x 10<sup>-5</sup>), indicating its utility over measures of proliferation as a 170 prognostic tool.

171

172 Next, we evaluated published prognostic signatures for breast cancers and compared 173 their performance with ENDORSE. These signatures included PAM50, a 50-gene

174 signature that was previously reported to be a better prognostic tool for ER+ breast 175 cancers on endocrine therapy than clinical factors, such as histopathological  $176$  classification and tumor grade<sup>28</sup>. A genomic classifier, IntClust, that developed by the 177 METABRIC consortium authors and trained on the same training dataset was also 178 included in this comparison<sup>29</sup>. The PAM50 model ( $D_{xy} = 0.220$ ) performed better than 179 IntClust ( $D_{xy} = 0.153$ ), however the ENDORSE model outperformed both PAM50 (P =  $180$   $0.033$ ) and IntClust (P = 0.02) models.

181

 $182$  Two previous clinical trials evaluating endocrine therapy response in metastatic ER+ 183 breast cancers developed prognostic signatures using tumor transcriptomes. The first 184 signature developed in the TransCONFIRM trial included 37 genes that were associated  $185$  with PFS of advanced ER+ breast cancers on fulvestrant<sup>19</sup>. We replicated the approach 186 described in the study by performing hierarchical clustering of the samples based on the 187 expression levels of the 37 genes and cutting the tree to obtain two clusters. We 188 referred to resultant clusters as the 'TransCONFIRM' score. The TransCONFIRM score 189 applied to the METABRIC dataset performed poorly ( $D_{xy}$  = -.002), suggesting that the 190 signature performed no better than a random set of genes and was unsurprisingly 191 outperformed by ENDORSE (P =  $9.73 \times 10^{-6}$ ).

192

193 The second signature (SET ER/PR) was developed using tumor transcriptomes of 194 metastatic ER+ breast cancers on endocrine therapy<sup>18</sup>. This signature included 18 195 predictive genes that were correlated with *ESR1* or *PGR* expression and normalized 196 using 10 reference transcripts. We implemented the methods described in original study

197 and referred to the resultant score as 'SET'. The SET score ( $D_{xy} = 0.152$ ) performed 198 better than TransCONFIRM; however, it was also easily outperformed by ENDORSE (P  $199 = 3.53 \times 10^{-5}$ ).

200

201 Finally, we calculated a surrogate based on the published formula for the 21-gene 202 prognostic signature approved for early-stage, node-negative  $ER+$  breast cancers  $30$ . <sup>203</sup>We referred to this score as ODX. We also compared a classifier that stratified samples  $204$  based on  $25<sup>th</sup>$  percentile of ODX score as a proxy for the latest risk stratification  $205$  threshold for this signature<sup>8</sup>, and referred to this score as ODX25. We found that the 206 ODX model ( $D_{xy}$  = 0.159) was comparable to other published signatures like the SET 207 score but the stratified ODX25 score performed poorly ( $D_{xy} = 0.056$ ). Again, the 208 ENDORSE model performed significantly better than both ODX ( $P = 6.15 \times 10^{-5}$ ) and 209 ODX25 (P =  $1.32 \times 10^{-5}$ ) models. These results show that ENDORSE is significantly 210 better prognostic model than available gene signatures, clinical factors and proliferation  $211$  index for endocrine therapy in the METABRIC dataset.



#### B



213

<sup>214</sup>**Figure 2: Model evaluation and comparison with other predictors** a. Lollipop plots 215 displaying corrected Somer's  $D_{xy}$  indices of ENDORSE and various other univariate Cox 216 proportional hazards models. The indices were calculated using 150-fold bootstrap 217 resampling of the training dataset. b. Table comparing the ENDORSE model with 218 various other univariate Cox models using partial likelihood ratio tests. The comparison

219 between the nested ENDORSE model and its two components were performed using a 220 likelihood ratio test, while other non-nested univariate models were compared using a 221 partial likelihood ratio test.

222

## <sup>223</sup>**Validation and performance evaluation in independent clinical trial datasets**

224 To test the reproducibility and validate the performance of ENDORSE, we applied the 225 model to the baseline transcriptomes of ER+ tumors from three independent clinical 226 trials and compared the ENDORSE-predicted risk or strata with the outcomes reported 227 in each trial. These independent trials also included the TransCONFIRM and SET 228 ER/PR studies discussed earlier. So, we also compared the performance of 229 TransCONFIRM and SET scores in their respective training datasets and also across 230 other independent datasets.

231

232 The TransCONFIRM trial evaluated fulvestrant response in 112 advanced metastatic 233 ER+ breast cancers previously treated with an antiestrogen<sup>19</sup>. While the original study 234 developed and evaluated the performance of their 37-gene signature based on PFS,  $235$  this survival data was not made available with the publication (the authors did not 236 respond to our requests for this data). However, the study reported the post-therapy 237 resistant or sensitive states of the tumors based on histopathological staining (Ki67  $238$  staining). Therefore, we compared the percentage of cells positive for Ki67 staining 239 reported by in study with risk predictions from ENDORSE and other signatures (Figure 240 3). The percentage of cells positive of Ki67 were significantly correlated with the 241 ENDORSE estimated risk (P = 2.5 x 10<sup>-5</sup>) (Figure 3a), while stratification of the patients

 $^{14}$ 



247

 $248$  Next, we evaluated the performance of the signatures in the SET ER/PR cohort. This 249 clinical trial reported the PFS and OS of 140 stage IV ER+ metastatic breast cancers on 250 endocrine therapy. We compared the survival curves of the patients by stratifying them  $251$  based on the ENDORSE predicted risk, median SET scores, as described in the original 252 study, and the TransCONFIRM score. The stratification based on ENDORSE (Figure <sup>253</sup>4a) and SET (Figure 4b) scores both resulted in significant differences in the survival 254 curves (ENDORSE P = 2 x 10<sup>-4,</sup> SET P = 3 x 10<sup>-3</sup>). However, the TransCONFIRM score 255 (Figure 4c) was not significant (P = 0.9). Similarly, we observed that ENDORSE (Figure  $256$  4d) and SET (Figure 4e) scores both resulted in significant differences in the PFS 257 curves (ENDORSE P = 1 x 10<sup>-6,</sup> SET P = 5 x 10<sup>-3</sup>), while TransCONFIRM was not 258 significant (P = 0.2). Additionally, we compared the model fits using partial likelihood 259 ratio tests. The SET model that was trained using the same dataset was not a better fit 260 than the ENDORSE mode (OS P = 0.667, PFS P=0.258). The ENDORSE model was a 261 better fit than the TransCONFIRM model in each case (OS  $P = 0.046$ , PFS P=0.038).  $262$  In addition to the two metastatic ER+ breast cancer trials, we also evaluated the 263 performance of the signatures examined data from the ACOSOG Z1031B clinical trial  $264$  which evaluated neoadjuvant aromatase inhibitor (AI) treatment in Stage II or III ER+

 $265$  breast cancers<sup>31</sup>. This study reported percentage of Ki67 staining both at the study 266 baseline and at the end of treatment (2-4 weeks). We compared the percentage of Ki67 267 positive cells across cancers stratified by the ENDORSE score and found significant 268 difference across the classes at both the baseline (P =  $4.9 \times 10^{-9}$ ) and at the end of 269 treatment (P = 3 x 10<sup>-18</sup>) (Figure 5a). Similarly, the continuous ENDORSE scores were 270 significantly correlated with both the baseline (P =  $3.3 \times 10^{-15}$ ) and end of treatment (P = 271 1.1 x 10<sup>-17</sup>) Ki67 percentage (Figure 5b). The ENDORSE scores were also significantly  $272$  higher in the tumors that were classified as resistant based on clinical response (P = 4.6)  $273 \times 10^{-6}$ ) (Figure 5c). In this cohort, the SET score was also significantly correlated with 274 Ki67 percentage at the baseline (P =  $2.8 \times 10^{-5}$ ) and end of treatment (P =  $2.2 \times 10^{-4}$ ) 275 (Figure 5d), with significant difference in the SET scores between the resistant and 276 sensitive tumors (P = 0.05) (Figure 5e). The transCONFIRM scores were not significant  $277$  at the baseline (P = 0.5) and end of treatment (Figure 5f) or between resistant and 278 sensitive tumors  $(P = 0.7)$  (Figure 5g).

279

280 In addition to the endocrine therapy trials in ER+ breast cancer, we also applied the 281 ENDORSE risk estimates to stratify 429 ER-negative METABRIC breast cancers as 282 negative controls. Kaplan-Meier analyses show no significant difference between the  $283$  strata (P = 0.26, Supplementary Figure 2). This suggests that the ENDORSE model is  $284$  specific to the ER+ cohort and not a general prognostic model.

285

 $10<sup>1</sup>$ 



286

<sup>287</sup>**Figure 3: Model validation in TransCONFIRM cohort.** A. Scatter plot comparing <sup>288</sup>ENDORSE scores (X-axis) with trial-reported percentage of cells stained positive for 289 Ki67 (Y-axis). Linear fit is shown as a grey line with shaded region showing 95% 290 confidence intervals (C.I.). P-value indicates significance of the linear fit. B. Boxplot 291 comparing Ki67 % across ENDORSE-guided patient strata. P-value indicates 292 significance of the ANOVA model and the horizontal dotted line at 10% indicates

- 293 threshold of resistance. C. Scatter plot comparing SET scores (X-axis) Ki67 % (Y-axis).
- <sup>294</sup>Linear fit is shown as a grey line with shaded region showing 95% confidence intervals
- 295 (C.I.). P-value indicates significance of the linear fit. B. Boxplot comparing Ki67 %
- 296 across TransCONFIRM predicted patient strata. P-value indicates significance of the
- <sup>297</sup>ANOVA model and the horizontal dotted line at 10% indicates threshold of resistance.



- 301 risk tables of SET ER/PR patients. The patients were stratified according to A.
- ENDORSE B. SET and C. TransCONFIRM predicted scores. P-values indicate
- significance of difference in survival curves based on log-rank tests. D-F PFS Kaplan-
- Meir curves and risk tables of SET ER/PR patients. The patients were stratified

- 305 according to A. ENDORSE B. SET and C. TransCONFIRM scores. P-values indicate
- 306 significance of difference in survival curves based on log-rank tests. G. Table comparing
- 307 the ENDORSE overall and PFS models with SET and TransCONFIRM models using
- 308 partial likelihood ratio tests for non-nested Cox models.



<sup>310</sup>**Figure 5: Model validation in ACOSOG Z1031B cohort.** A. Boxplots comparing Ki67 311 % at the baseline (left panel) and end of treatment (right panel) across ENDORSE-312 predicted patient strata. P-value indicates significance of the ANOVA model and the 313 horizontal dotted line at 10% indicates threshold of resistance. B. Scatter plot comparing <sup>314</sup>ENDORSE scores (X-axis) and Ki67 % (Y-axis) at the baseline (left panel) and end of 315 treatment (right panel). Linear fit is shown as a grey line with shaded region showing <sup>316</sup>95% confidence intervals (C.I.). P-value indicates significance of the linear fit. C. 317 Boxplots comparing ENDORSE scores between patients classified as resistant or 318 sensitive clinical response. P-value indicates significance of the ANOVA model. D. 319 Scatter plot comparing SET scores (X-axis) and Ki67 % (Y-axis) at the baseline (left 320 panel) and end of treatment (right panel). Linear fit is shown as a grey line with shaded 321 region showing 95% confidence intervals (C.I.). P-value indicates significance of the 322 linear fit. E. Boxplots comparing SET scores between patients classified as resistant or 323 sensitive clinical response. P-value indicates significance of ANOVA model. F. Boxplots 324 comparing Ki67 % at the baseline (left panel) and end of treatment (right panel) across 325 TransCONFIRM-predicted patient strata. P-value indicates significance of the ANOVA 326 model and the horizontal dotted line at 10% indicates threshold of resistance. G. 327 Boxplots comparing TransCONFIRM predictions between patients classified as 328 resistant or sensitive clinical response. P-value indicates significance of ANOVA model 329 330

#### <sup>332</sup>**Common pathway phenotypes and somatic alterations enriched in high-risk**

#### <sup>333</sup>**tumors**

334 We analyzed the pathway phenotypes enriched in each dataset to identify potential 335 mechanisms that defined the high-risk tumors. First, we calculated the GES for 50 336 hallmark, 4690 curated and 189 oncogenic signatures from the METABRIC 337 transcriptomes and fitted a generalized additive model for ENDORSE scores with each  $338$  signature as the predictor (Supplementary Tables 2-4). We found multiple hallmark 339 signatures and oncogenic pathways to be significantly associated with the ENDORSE 340 scores (Supplementary Tables 2-4). Key enriched hallmark signatures included MTOR 341 signaling (P =  $1.03 \times 10^{-72}$ ) and MYC targets (v2, P =  $2.66 \times 10^{-83}$ ), while key oncogenic  $342$  signatures included gain in E2F1 target expression (P = 8.06x10<sup>-302</sup>) and loss of RB1 343 activity via p107 and p130 (P =  $9.51x10^{-137}$ , 1.31x10<sup>-67</sup>) (Supplementary Tables 2, 4). 344 Next, we calculated the GES for the hallmark and oncogenic signatures in the three 345 validation datasets (Supplementary Tables 5-10). We observed that pathways 346 associated with cell-cycle progression and proliferation, along with signatures for the 347 loss of RB-1 activity and activation of the PI3K/AKT/MTOR signaling pathways were 348 generally enriched across the METABRIC and all the three validation datasets (Figure 349 6a). Similar to the training dataset, we also found gain in cell cycle progression along 350 with MTOR signaling and E2F1 target expression to be associated with high ENDORSE 351 scores across all datasets (Figure 6a, Supplementary Tables 5-10). The commonality of 352 the signatures enriched across different datasets suggested similar underlying 353 phenotypes were acquired by the high-risk tumors.

 $^{23}$ 

354 We also analyzed the association between gene-level somatic mutations, including non-355 synonymous single-nucleotide variants (SNV) and copy number alterations, with the <sup>356</sup>ENDORSE scores of the METABRIC ER+ tumors. We found a statistically significant  $357$  association (FDR  $< 0.05$ ) between the ENDORSE scores and SNVs of only five genes <sup>358</sup>(Figure 6b, Supplementary Table 11). While *PIK3CA* mutations were found in ~50% of 359 all tumors, we found that ENDORSE scores were not significantly higher in tumors with 360 non-synonymous *PIK3CA* variants or activating *PIK3CA* variants that guide the use of 361 PI3K inhibitors (Supplementary Figure 3). Of the five significant genes, only tumors with <sup>362</sup>*TP53* mutations showed a significantly higher ENDORSE score (Figure 6b). We then  $363$  performed bootstrap analyses with the univariate Cox models of the significant genes <sup>364</sup>and found that none of the SNV Cox models performed better than the ENDORSE 365 model (Figure 6b).

366

367 Several gene-level amplifications were also associated with significant differences in <sup>368</sup>ENDORSE scores (Figure 6c, Supplementary Figure 4). Interestingly, the significant 369 amplifications were localized at chromosome 1q, 8p, 8q, or 11q, suggesting different 370 genetic alterations affecting a recurring set of loci may be correlated with the 371 emergence of resistance in the high-risk tumors (Figure 6c, Supplementary Table 12). 372 Like the univariate SNV models above, the univariate copy number alteration models 373 also performed poorly when compared to the ENDORSE model in bootstrap resampling 374 analyses (Figure 6d).

375



 $\ddotsc$ 

<sup>377</sup>**Figure 6: Biology of the high-risk tumors**. A. Scatter plots displaying gene set 378 enrichment scores (GES) of key pathways (X-axis) and ENDORSE scores (Y-axis). The

379 cell cycle progression panel represents the hallmark G2M checkpoint signature, the

<sup>380</sup>E2F1 upregulation panel represents E2F1\_UP.V1\_UP oncogenic (C6) signature and 381 the MTOR upregulation panel represents MTOR\_UP.V1\_UP oncogenic (C6) signature.  $382$  Blue lines with shading indicate generalized additive model fits with 95% C.I., with R<sup>2</sup> 383 and p-values of the significant of the fit annotated on the panels. B. Barplots showing p- $384$  values from the ANOVA analysis of ENDORSE scores with mutation status as the 385 grouping variable. The boxplot on the right shows difference in the ENDORSE scores 386 between *TP53* mutant and wildtype tumors. The lollipop plot below shows Somer's D<sub>xy</sub>  $387$  of the univariate Cox models for the SNVs, with the vertical dotted line indicating D<sub>xy</sub> of 388 the ENDORSE model. C. Ideograms showing mapped regions with copy number gains 389 that are significant in ANOVA analysis of ENDORSE scores with copy number gain 390 status as the grouping variables. Barplots on the right show p-values from the ANOVA 391 analysis. D. Lollipop plot showing Somer's  $D_{xy}$  of the univariate Cox models for the copy  $392$  number gains, with the vertical dotted line indicating  $D_{xy}$  of the ENDORSE model. 393

#### <sup>394</sup>**DISCUSSION**

 $395$  The criteria for classifying tumor as ER+ is based on a broad criteria of positive 396 immunohistochemical staining of 1-100% of cell nuclei for the estrogen receptor  $14,32$ . 397 However, ER+ tumors are heterogeneous, both in terms of dependence on estrogen 398 signaling for growth and survival and intrinsic or acquired resistance to endocrine 399 therapy <sup>33,34</sup>. Therefore, optimal clinical management of each ER+ breast cancer 400 depends on accurate prediction of response to endocrine therapy and selection of 401 companions for endocrine therapy. Several genomic tests are available for classifying  $402$  breast cancers into molecular subtypes  $35$  or assessing the likelihood of benefit from 403 chemotherapy in early-stage, node-negative ER+ breast cancers  $7,30$ . Results from the  $404$  MINDACT and TAILORx studies<sup>7,8</sup> show that it is possible for node-negative, early-405 stage breast cancers to safely waive additional chemotherapy if they are predicted to be 406 at a low risk of recurrence based on genomic signatures. However, these tests have not  $407$  proven to be useful in the advanced and metastatic ER+ breast cancer setting. The  $408$  default primary treatment for advanced ER+ breast cancer remains endocrine therapy, 409 despite proven benefit from add-on targeted therapy or potential switch to  $410$  chemotherapy. Therefore, the key challenge in advanced ER+ breast cancer is to 411 stratify patients that will likely benefit from continued endocrine therapy and patients that 412 are likely resistant to single-agent endocrine therapy and will benefit from selecting a 413 different treatment strategy<sup>36</sup>.

414

415 To address this challenge, we have developed a new prognostic model to predict

416 endocrine response in advanced ER+ breast cancers. We developed our model using

 $417$  invasive tumors from the METABRIC study that were ER+ and included node-positive, 418 high-grade tumors. Our model addressed several challenges associated with the 419 development of genomic biomarkers. Since the number of available features to train the 420 genomic models tend to be much larger than the number of available samples ( $p \gg n$ ),  $421$  it is quite easy to create complex prediction models that contain a large number of 422 predictor variables. Often, such models perform very well in the training datasets, but 423 the performance cannot be replicated in independent test datasets due to overfitting. A 424 number of approaches have been proposed to address this issue. Broadly, these can  $425$  be classified into unsupervised and supervised approaches. The unsupervised 426 approach typically relies on grouping or clustering the samples into based on similarity 427 of gene expression profiles, followed by analysis of association with survival outcomes  $428$   $37$ . Alternatively, a supervised approach is to perform dimensionality reduction prior to 429 modelling the survival outcome or drug response using univariate or multivariate models  $430$   $38$ . Our model utilized the later strategy by using a regularized Cox model for feature 431 selection, effectively reducing the dimensionality of the gene expression data. We 432 further collapsed the genes into a signature and parameterized the final Cox model on 433 the GES of the signatures. The rank-based approach to calculate GES also helped 434 mitigate issues associated with batch effects and differences in methods for 435 transcriptome profiling. We performed extensive performance evaluation of our model 436 against other published signatures and clinical factors. Consistently, we found that the 437 ENDORSE model was a better predictor than all other models in the training dataset 438 (Figure 2). Moreover, ENDORSE clearly outperformed all other published signatures 439 when they were applied to external validation datasets (Figures 3-5). Our results show

440 that ENDORSE is a highly accurate and reproducible model that outperforms current 441 approaches to predict endocrine response in metastatic ER+ breast cancer.

442

443 We also explored the biology of the ER+ tumors to identify possible mechanisms that 444 are commonly shared by high-risk tumor. We found that high-risk tumors showed a 445 consistent enrichment of pathways associated cell cycle progression and gain of 446 PI3K/MTOR signaling pathways (Figure 6a). In addition, we observed consistent gain of  $447$  the E2F1 signature, which may be associated with metastatic progression of breast  $448$  cancers<sup>39,40</sup>. We also observed loss of Rb1 activity, which has been associated with

449 therapeutic resistance in ER+ breast cancers  $41,42$ 

450

 $451$  In addition to common pathway phenotypes shared across high-risk tumors, mutations <sup>452</sup>in the *TP53* tumor suppressor genes were also significant (Figure 6b). Loss of function <sup>453</sup>*TP53* variants have long been associated with aggressiveness and chemotherapeutic 454 resistance in hormone-receptor negative breast cancers  $43,44$ . However, recent studies 455 show that even though *TP53* mutations are infrequent in ER+ breast cancers, they have 456 similar negative impact on patient outcome as hormone-receptor negative breast  $457$  cancers<sup>45</sup>. We also found recurrent copy number gains at chromosomes 8 and 11 to be 458 associated with high-risk tumors (Figure 6c). Amplifications at these loci have been 459 previously associated with aggressive and drug resistant cancers, and included several 460 oncogenes such as *MYC*, *CCND1* and multiple fibroblast growth factors <sup>46,47</sup>. The  $461$  survival models based on genomic alterations were clearly outperformed by ENDORSE;

462 however, the recurrent nature of these alterations in high-risk tumors suggests further 463 studies to investigate their role in promoting endocrine resistance are warranted.



## <sup>479</sup>**METHODS**

#### <sup>480</sup>**Data retrieval and pre-processing**

- <sup>481</sup>METABRIC gene expression, phenotypic and survival data were retrieved using
- $482$  cBioPortal for cancer genomics<sup>49</sup>. Independent validation datasets used in this study
- 483 were retrieved from the NCBI Gene Expression Omnibus database with the following
- 484 accession IDs: SET ER/PR GSE124647<sup>18</sup>, TransCONFIRM GSE76040<sup>19</sup>, and
- $485$  ACOSOG Z1031B GSE87411<sup>31</sup>. For each gene expression dataset (log2 transformed),
- 486 we removed genes with zero variance and summarized genes with multiple probes by
- 487 mean expression and scaling of the expression levels of each gene to a mean of zero
- 488 and standard deviation of one.
- 489

#### <sup>490</sup>**Inclusion criteria for METABRIC training cohort**

491 The METABRIC cohort contained a total of 2509 samples. Samples that met all of the

492 following criteria were included in the training cohort: patients that were ER-positive and

493 HER2-negative based on immunohistochemistry, patients that received hormone

494 therapy but did not receive additional chemotherapy, patients that were either alive or

495 died due to the disease and no other causes, and patients with complete survival and

496 transcriptomic data. After filtering, 833 samples were retained for model construction.

497

#### <sup>498</sup>**Empirical signature and ENDORSE model construction**

499 The empirical gene signature was developed using a LASSO-regularized Cox

 $500$  proportional hazards models, with OS as the outcome variable<sup>50</sup>. The hazard function in

 $501$  the Cox model is defined as:

$$
h_i(t) = h_0(t) \exp (\beta x_i^T)
$$

 $502$  Where, X is a set of predictive gene expression features and  $h_0$  is an arbitrary baseline  $503$  hazard function. The coefficient (β) for each predictor in the model can be estimated by  $504$  maximizing the partial likelihood function  $L(β)$ , defined as:

$$
L(\beta) = \prod_{i} \frac{\exp(\beta x_{j(i)}^T)}{\sum_{l \in R_i} \exp(\beta x_j^T)}
$$

 $505$  Where R<sub>i</sub> is the set of indices of observations failing (events) at time t<sub>i</sub>. In the LASSO  $506$  Cox model, the regularized coefficient is obtained by adding a penalty parameter  $\lambda$  to 507 the log of the likelihood function.

$$
\hat{\beta} = \min -\frac{1}{N}l(\beta) + \lambda ||\beta||_1
$$

508 Where,  $I(\beta) = \log L(\beta)$ . The λ penalty parameter was determined using 10-fold cross-509 validation implemented in R package glmnet  $36,37$ . The optimal  $\lambda$  minimized model 510 deviance.

511

We applied the model in a repeated (50 x 10-fold) cross validation framework. In each iteration, a set of 'seed genes' or features with positive coefficients in the regularized Cox model at a  $\lambda$  equal to one standard error from the minimum model deviance were 515 identified. The seed genes were expanded to a redundant correlation network by adding all genes in the training transcriptome dataset that had Pearson's correlation  $> 0.75$  with 517 any of the seed genes. Across all iterations, we identified the common set of features that were present in at least 50% of the correlation networks and defined this set of 519 features as the empirical signature.

520

 $3<sup>2</sup>$ 

521 The ENDORSE model was defined as the hazard's ratio of the Cox proportional 522 hazards model fitted on OS data of the training cohort with two components: GES for 523 the empirical gene signature and GES for the hallmark estrogen early response 524 signature.

$$
h(t) = h_0(t) \times \exp(\beta_{emp} GES_{emp} + \beta_{er} GES_{er})
$$

<sup>525</sup>where, *emp* represents the empirical signature and *er* represents the estrogen response 526 signature.

527 For each signature, the GES were calculated for individual samples using the GSVA  $528$  package for  $R^{53}$  using the ssGSEA method<sup>54</sup>. The parameters for the ENDORSE model 529 were obtained by fitting the model to the full training cohort of 833 samples, resulting in 530  $\beta_{\text{emo}} = 1.54$  and  $\beta_{\text{er}} = -2.72$ .

531

#### <sup>532</sup>**Models based on external signatures and clinical factors**

533 Clinical features such as tumor grade and mutation count, along with scores from

534 PAM50 and IntClust analyses were obtained directly from the METABRIC clinical

535 annotations accompanying the transcriptome data and were directly utilized in

536 univariate Cox models. Proliferation index based on the metaPCNA signature was

537 calculated using the R-package ProliferativeIndex $27$ .

538 We replicated the signatures and algorithms developed in the TransCONFIRM, SET

<sup>539</sup>ER/PR and 21-gene prognostic signature studies by following the methods described in

- 540 the respective studies. The TransCONFIRM signature composed of 37 genes was
- 541 implemented by performing hierarchical clustering of the gene expression data using
- $542$  these genes and cutting the tree (k=2) to stratify samples in high or low TransCONFIRM

543 score categoties. The SET signature was implemented by calculating (the average  $544$  expression of the 18-genes in the signature) – (the expression of 10 house-keeping  $545$  genes) + 2. The 21-gene signature (ODX) score was calculated by following the 546 unscaled risk score calculation reported by the study. *BAG1* transcript was missing from 547 the METABRIC cohort and was not included in the unscaled score calculation. Since  $548$  this transcript was uniformly missing on all samples, the relative risk scores could be 549 compared across the samples. 550

# <sup>551</sup>**Cox model performance evaluation in training data**

552 The predictive ability of ENDORSE and various other models were evaluated in the <sup>553</sup>METABRIC training dataset using a bootstrap resampling analysis of the Cox 554 regression models. The resampling was repeated 150 times for each model and a 555 Somer's  $D_{xy}$  rank correlation was calculated in each repeat. A final bias-corrected index  $556$  of Somer's D<sub>xy</sub> was obtained as measure of the model's predictive ability. The bootstrap  $557$  resampling and calculations of the Somer's  $D_{xy}$  were performed using the R package 558 "rms'. Models based on SNVs and CNAs significantly associated with ENDORSE scores  $559$  were also evaluated by obtaining Somer's  $D_{xy}$  rank correlation metric of the univariate 560 Cox model.

561

<sup>562</sup>To compare each of the external signatures and clinical feature models with the

 $563$  ENDORSE model, we applied Vuong's<sup>55</sup> partial likelihood ratio test for non-nested Cox

564 regression models calculated using the R package 'nonnestcox'

<sup>565</sup>(https://github.com/thomashielscher/nonnestcox/). The individual components of the

- <sup>566</sup>ENDORSE model were compared to the full model using likelihood ratio tests for nested
- 567 Cox models.
- 568
- <sup>569</sup>**Model validation in independent datasets**
- 570 We compared the predictive performance of ENDORSE in multiple independent
- 571 datasets. First, we integrated the training (METABRIC) and test (independent validation)
- 572 datasets to perform batch correction using the ComBat function of the R package 'sva
- 573 <sup>56</sup>. Next, we calculated the GES for the ENDORSE signatures in the training
- <sup>574</sup>(METABRIC) and test (independent validation) splits of the batch-corrected gene
- 575 expression dataset. Then, the parameters of the ENDORSE Cox model were calculated
- $576$  on the batch-corrected training split with the OS information as the response variable.
- 577 Finally, the parameterized Cox model was applied to the test split to obtain a predicted
- $578$  risk score.
- 579

580 In case of the SET ER/PR cohort, we used the predicted ENDORSE risk scores to  $581$  stratify the patients into risk categories, with an ENDORSE score ≥2 representing the <sup>582</sup>high-risk group, ≤1 representing the low-risk group and other intermediate values  $583$  representing the medium risk group. We compared the significance of stratification of 584 both OS and PFS curves based on ENDORSE, SET and TransCONFIRM scores using  $585$  log-rank tests. Further, we compared the models using partial likelihood ratio tests for 586 non-nested Cox models.

587

 $35<sub>5</sub>$ 

588 For the TransCONFIRM and ACOSOG cohorts, we compared the ENDORSE risk 589 scores, SET and TransCONFIRM predictions with reported clinical variables, such as 590 percentage of cells positive for Ki67 at the end of treatment and clinical outcomes using 591 generalized linear models for continuous outcome variables or one-way ANOVA 592 analysis for categorical outcomes. 593 <sup>594</sup>**Biological features associated with ENDORSE scores**  595 To determine the possible biological mechanisms associated with emergence of 596 endocrine resistance and high ENDORSE risk scores, we evaluated the enrichment 597 scores of various biological pathway and oncogenic signatures across the training and 598 independent validation cohorts. We used the ssGSEA method to obtain GES for 599 hallmark, curated (C2) and oncogenic signature (C6) gene sets from the molecular  $600$  signatures database<sup>57</sup>. For each signature, we fitted a generalized additive model 601 against the predicted ENDORSE score to obtain significance of the fit,  $R^2$  and 602 proportion of variance explained by the model. None of the curated signatures were <sup>603</sup>significant in the METABRIC analyses and were excluded from further consideration in  $604$  the independent validation datasets.

605

<sup>606</sup>Gene-level somatic SNV and CNV analyses were performed using data reported by the  $607$  METABRIC study. SNV's were retained based on a mutation frequency of ≥5 across all <sup>608</sup>samples and limited to genes that are known cancer-related genes. Pathogenic *PIK3CA*  609 variants associated with PI3K inhibitor sensitivity were obtained from the drug labels for 610 alpelisib based on the SOLAR1 clinical trial<sup>12</sup>. Significant SNVs and CNVs were

 $3<sup>0</sup>$ 

- 611 obtained using a one-way ANOVA analysis of the ENDORSE scores with mutation
- $612$  status as the factor.
- 613

#### <sup>614</sup>**Data availability and code**

- $615$  All training and validation datasets used in this study are publicly available and listed
- 616 under "data retrieval, preprocessing and analysis". All analyses were performed in
- <sup>617</sup>RStudio (1.2.5033, R 3.6.3). The sample code for reproducing the analyses in this study
- 618 are available at https://osf.io/bd3m7/?view\_only=da4f860bd2474745880944fce1d433b1
- 619

# <sup>620</sup>**ACKNOWLEDGEMENTS**

- 621 Funding for this research was provided by the National Cancer Institute of the National
- 622 Institutes of Health through the U54 grant 1U54CA209978.

623

# <sup>624</sup>**AUTHOR CONTRIBUTIONS**

- 625 Conceptualization, Methodology, Investigation AN, ALC, AHB; Data Curation, Formal
- <sup>626</sup>Analysis, Software, Visualization, Validation AN; Funding Acquisition, Resources,
- 627 Supervision, Project Administration ALC, AHB; Writing original draft AN; Writing –
- $628$  review & editing AN, ALC, AHB.
- 629

# <sup>630</sup>**CONFLICT OF INTERESTS**

 $631$  The authors declare that they have no conflict of interest.

#### **REFERENCES**

- 1. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
- and Mortality Worldwide for 36 Cancers in 185 Countries. *CA A Cancer J Clin* **<sup>71</sup>**,
- 209–249 (2021).
- 2. Harvey, J. M., Clark, G. M., Osborne, C. K. & Allred, D. C. Estrogen receptor status
- by immunohistochemistry is superior to the ligand-binding assay for predicting
- response to adjuvant endocrine therapy in breast cancer. *J. Clin. Oncol.* **<sup>17</sup>**, 1474–
- 639 1481 (1999).
- 3. Kohler, B. A. *et al.* Annual Report to the Nation on the Status of Cancer, 1975-2011,
- 641 Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and
- State. *JNCI: Journal of the National Cancer Institute* **<sup>107</sup>**, (2015).
- 4. Waks, A. G. & Winer, E. P. Breast Cancer Treatment: A Review. *JAMA* **<sup>321</sup>**, 288 644 (2019).
- 5. McDonnell, D. P. & Wardell, S. E. The molecular mechanisms underlying the
- pharmacological actions of ER modulators: implications for new drug discovery in
- breast cancer. *Current Opinion in Pharmacology* **<sup>10</sup>**, 620–628 (2010).
- 6. Smith, I. E. & Dowsett, M. Aromatase Inhibitors in Breast Cancer. *N Engl J Med* **<sup>348</sup>**,
- 2431–2442 (2003).
- 7. Cardoso, F. *et al.* 70-Gene Signature as an Aid to Treatment Decisions in Early-
- Stage Breast Cancer. *https://doi.org/10.1056/NEJMoa1602253*
- https://www.nejm.org/doi/10.1056/NEJMoa1602253 (2016)
- 653 doi:10.1056/NEJMoa1602253.



- 9. Krop, I. *et al.* Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy
- 657 for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical
- Oncology Clinical Practice Guideline Focused Update. *JCO* **<sup>35</sup>**, 2838–2847 (2017).
- 10. Duffy, M. J. *et al.* Clinical use of biomarkers in breast cancer: Updated guidelines
- from the European Group on Tumor Markers (EGTM). *European Journal of Cancer*
- **75**, 284–298 (2017).
- 11. McAndrew, N. P. & Finn, R. S. Management of ER positive metastatic breast
- cancer. *Seminars in Oncology* **<sup>47</sup>**, 270–277 (2020).
- 12. André, F. *et al.* Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive
- Advanced Breast Cancer. *New England Journal of Medicine* **<sup>380</sup>**, 1929–1940 (2019).
- 13. Baselga, J. *et al.* Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. *N Engl J Med* **<sup>366</sup>**, 520–529 (2012).
- 14. Rugo, H. S. *et al.* Endocrine Therapy for Hormone Receptor–Positive Metastatic
- Breast Cancer: American Society of Clinical Oncology Guideline. *JCO* **<sup>34</sup>**, 3069–3103 (2016).
- 15. Gradishar, W. J. *et al.* NCCN Guidelines Insights: Breast Cancer, Version
- 1.2017. *J Natl Compr Canc Netw* **<sup>15</sup>**, 433–451 (2017).
- 16. Gradishar, W. J. *et al.* Breast Cancer, Version 3.2020, NCCN Clinical Practice
- Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network* **<sup>18</sup>**,
- 452–478 (2020).

- 17. Cardoso, F. *et al.* 5th ESO-ESMO international consensus guidelines for
- advanced breast cancer (ABC 5). *Annals of Oncology* **<sup>31</sup>**, 1623–1649 (2020).
- 18. Sinn, B. V. *et al.* SET ER/PR: a robust 18-gene predictor for sensitivity to
- endocrine therapy for metastatic breast cancer. *NPJ Breast Cancer* **<sup>5</sup>**, 16 (2019).
- 19. Jeselsohn, R. *et al.* TransCONFIRM: Identification of a Genetic Signature of
- Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
- *Clin. Cancer Res.* **<sup>22</sup>**, 5755–5764 (2016).
- 20. Boutros, P. C. The path to routine use of genomic biomarkers in the cancer clinic.
- *Genome Res* **<sup>25</sup>**, 1508–1513 (2015).
- 21. Witten, D. M. & Tibshirani, R. Survival analysis with high-dimensional covariates. *Stat Methods Med Res* **<sup>19</sup>**, 29–51 (2010).
- 22. Taylor, J. M. G., Ankerst, D. P. & Andridge, R. R. Validation of Biomarker-Based Risk Prediction Models. *Clin Cancer Res* **<sup>14</sup>**, 5977–5983 (2008).
- 23. Pereira, B. *et al.* The somatic mutation profiles of 2,433 breast cancers refine
- their genomic and transcriptomic landscapes. *Nature Communications* **<sup>7</sup>**, 1–16
- 691 (2016).
- 24. Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **<sup>486</sup>**, 346–352 (2012).
- 25. Liberzon, A. *et al.* The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Systems* **<sup>1</sup>**, 417–425 (2015).
- 696 26. Venet, D., Dumont, J. E. & Detours, V. Most Random Gene Expression
- Signatures Are Significantly Associated with Breast Cancer Outcome. *PLOS*
- *Computational Biology* **<sup>7</sup>**, e1002240 (2011).



- 35. Parker, J. S. *et al.* Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. *J Clin Oncol* **<sup>27</sup>**, 1160–1167 (2009).
- 36. Hart, C. D. *et al.* Challenges in the management of advanced, ER-positive,
- HER2-negative breast cancer. *Nat Rev Clin Oncol* **<sup>12</sup>**, 541–552 (2015).
- 37. Sotiriou, C. *et al.* Breast cancer classification and prognosis based on gene
- expression profiles from a population-based study. *PNAS* **<sup>100</sup>**, 10393–10398 (2003).
- 38. Paul, D., Bair, E., Hastie, T. & Tibshirani, R. "Preconditioning" for feature
- selection and regression in high-dimensional problems. *Ann. Statist.* **<sup>36</sup>**, 1595–1618
- (2008).
- 39. Hollern, D. P., Honeysett, J., Cardiff, R. D. & Andrechek, E. R. The E2F
- Transcription Factors Regulate Tumor Development and Metastasis in a Mouse
- Model of Metastatic Breast Cancer. *Molecular and Cellular Biology* **<sup>34</sup>**, 3229–3243
- (2014).
- 40. Hollern, D. P. *et al.* E2F1 Drives Breast Cancer Metastasis by Regulating the

Target Gene FGF13 and Altering Cell Migration. *Sci Rep* **<sup>9</sup>**, 10718 (2019).

- 736 41. Bosco, E. E. *et al.* The retinoblastoma tumor suppressor modifies the therapeutic 737 response of breast cancer. *J Clin Invest* **117**, 218–228 (2007).
- 738 42. Witkiewicz, A. K. & Knudsen, E. S. Retinoblastoma tumor suppressor pathway in
- breast cancer: prognosis, precision medicine, and therapeutic interventions. *Breast*
- *Cancer Research* **<sup>16</sup>**, 207 (2014).
- 43. Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L. & Delia, D. P53 expression in breast cancer. *International Journal of Cancer* **<sup>41</sup>**, 178–183 (1988).



- 53. Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for
- microarray and RNA-Seq data. *BMC Bioinformatics* **<sup>14</sup>**, 7 (2013).
- 54. Barbie, D. A. *et al.* Systematic RNA interference reveals that oncogenic KRAS -
- driven cancers require TBK1. *Nature* **<sup>462</sup>**, 108–112 (2009).
- 55. Vuong, Q. H. Likelihood Ratio Tests for Model Selection and Non-Nested
- Hypotheses. *Econometrica* **<sup>57</sup>**, 307 (1989).
- 56. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva
- package for removing batch effects and other unwanted variation in high-throughput
- experiments. *Bioinformatics* **<sup>28</sup>**, 882–883 (2012).
- 57. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics*
- **27**, 1739–1740 (2011).







#### METABRIC cohort (ER+/HER2-, n = 833) A Prediction model validation (bootstrap resampling, B=150)



#### **B** Model comparisons





TransCONFIRM cohort (ER+ metastatic breast cancer, n = 112)





ACOSOG Z1031B cohort (stage II/III ER+ breast cancer, n = 109)

